Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Endocrine 3Sarcoma 2NET 2Head & Neck 1

Conditions

Parathyroid Neoplasms 1Multiple Endocrine Neoplasia 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × fluorodopa F 18 × Head & Neck × Clear all
NCT00001277 2022-06-07

Studies of Elevated Parathyroid Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
1,553 enrolled 8 charts
EndocrineHead & Neck

Hypercalcemia, Hyperparathyroidism, Hypoglycemia, Multiple Endocrine Neoplasia, Parathyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡